HUYA Bioscience International strengthens executive team

Appoints Alain Rolland as Executive Vice President and Chief Scientific Officer

HUYA Bioscience International (HUYA), a biopharmaceutical company with offices in the US, Japan and China, has made a key addition to its Executive Team with the appointment of Alain Rolland as Executive Vice President and Chief Scientific Officer.

Rolland brings 25 years of international leadership experience in the biopharma industry.

Most recently he was a Corporate Officer and Executive Vice President of Product Development at Vical, a biopharma R&D company developing cancer immunotherapeutics and infectious disease vaccines. He has also held positions at Ciba-Geigy, Galderma, GeneMedicine and Valentis.

You may also like

Research & Development

HUYA Bioscience and Zhongshan Technology Park form alliance

To accelerate discovery and development of biopharmaceuticals in China
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Subscribe now